open access

Vol 12, No 5 (2016)
Review paper
Published online: 2017-03-08
Get Citation

Treatment of advanced ovarian cancer with bevacizumab in Poland — a chance to improve survival still missed

Paweł Blecharz, Radosław Mądry, Marek Jasiówka
DOI: 10.5603/OCP.2016.0009
·
Oncol Clin Pract 2016;12(5):167-178.

open access

Vol 12, No 5 (2016)
REVIEW ARTICLES
Published online: 2017-03-08

Abstract

In Poland the use of bevacizumab, angiogenesis inhibitor, in the treatment of patients with advanced ovarian cancer is financed by the Ministry of Health within the existing Drug Program. Available data indicate that not all patients who could benefit from such a treatment finally receive it. There could be many different reasons for this situation — some are due to patients’ clinical characteristics, but other result from misunderstanding of the eligibility criteria and the rules of the treatment program by physicians. The presented publication discusses comprehensively some oncological criteria that could be a subject of discussion, and which make qualification to bevacizumab-containing treatment more difficult.  

Abstract

In Poland the use of bevacizumab, angiogenesis inhibitor, in the treatment of patients with advanced ovarian cancer is financed by the Ministry of Health within the existing Drug Program. Available data indicate that not all patients who could benefit from such a treatment finally receive it. There could be many different reasons for this situation — some are due to patients’ clinical characteristics, but other result from misunderstanding of the eligibility criteria and the rules of the treatment program by physicians. The presented publication discusses comprehensively some oncological criteria that could be a subject of discussion, and which make qualification to bevacizumab-containing treatment more difficult.  

Get Citation

Keywords

ovarian cancer, bevacizumab, treatment program

About this article
Title

Treatment of advanced ovarian cancer with bevacizumab in Poland — a chance to improve survival still missed

Journal

Oncology in Clinical Practice

Issue

Vol 12, No 5 (2016)

Article type

Review paper

Pages

167-178

Published online

2017-03-08

DOI

10.5603/OCP.2016.0009

Bibliographic record

Oncol Clin Pract 2016;12(5):167-178.

Keywords

ovarian cancer
bevacizumab
treatment program

Authors

Paweł Blecharz
Radosław Mądry
Marek Jasiówka

References (10)
  1. Krajowy Rejestr Nowotworów. www.onkologia.org.pl.
  2. Vergote I, Tropé CG, Amant F, et al. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10): 943–953.
  3. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386(9990): 249–257.
  4. Oza AM, Cook AD, Pfisterer J, et al. ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015; 16(8): 928–936.
  5. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334(1): 1–6.
  6. Wimberger P, Lehmann N, Kimmig R, et al. Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2007; 106(1): 69–74.
  7. Nick AM, Coleman RL, Ramirez PT, et al. A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol. 2015; 12(4): 239–245.
  8. Fagotti A, Ferrandina G, Vizzielli G, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer. 2016; 59: 22–33.
  9. Zalewski K, Misiek M, Góźdź S, et al. Nowy system klasyfikacji zaawansowania nowotworów jajnika, jajowodu i otrzewnej — stan na 2014 rok. Onkologia w Praktyce Klinicznej. 2015; 11: 129–134.
  10. Alexander M, Blum R, Burbury K, et al. Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice. Intern Med J. 2017; 47(1): 16–34.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl